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Abstract
Many women are concerned about their future fertility, about pregnancy complications 
and about the health of their future child when choosing a contraceptive method and 
sometimes women want to interrupt the contraception – maybe after years of use – in 
order to attempt pregnancy. Return to fertility, has been thoroughly analyzed in the lit-
erature. This chapter provides evidence-based information and discusses the potential 
doubts of women. Return to fertility has been consistently found to be sure, albeit some-
times slightly slow in the short term: pregnancy rates after 1 year of contraceptive inter-
ruption are 79–95% for oral contraceptives, 79–96% for levonorgestrel IUD, 71–91% for 
copper IUDs, around 80% for implants and 75–80% for injectable contraceptives. About 
50% women are pregnant 3–6 months after contraceptive discontinuation; around 90–95% 
of women had achieved pregnancy 2 years after stopping their contraceptive method. 
Some studies have found associated risks of fetal malformations when women take oral 
contraceptive pills after conception (though other studies disputed these results). However 
the offspring of women who used oral contraceptives before conception does not show an 
increased risk of fetal death, miscarriage, gestational hypertension, major newborn struc-
tural defects or hypospadias. The effect on birth weight seems small and inconclusive.
Keywords: return to fertility, contraceptive, UID, copper, pill, contraceptive implant, 
hormonal contraceptive, injectable, depot, pregnancy rate
1. Introduction
Contraceptive methods are the instrument that women use to control their fertility at any 
given time in their lives so that the pregnancy would be produced by choice and not by 
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chance. In any case, women’s reproductive goals change at any moment of the woman’s fer-
tile life; this is why the reversibility of the chosen method is especially important for them [1].
For many authors, infertility refers to the inability of a couple to conceive after having 
12 months of regular sexual intercourse without using any contraceptive method; some 
authors emphasize intercourse “in the fertile phase of the menstrual cycles” [2]. Infertility rate 
is better estimated by prospective studies; around 80% women become pregnant in the first 
cycles and approximately, 85–90% couples will conceive within 1 year if they have regular 
unprotected sex. 50% of couples who did not manage to conceive after 12 months (infertility 
definition) will manage to conceive spontaneously in the next 36 months; after this time point 
spontaneous conception in infertile couples is considered only sporadic [2]. Infertility (both 
male and female) is influenced by many reproductive or lifestyle factors. Physical causes of 
female infertility include alterations in ovulation and abnormal functioning or structures of 
reproductive organs, as well as age and lifestyle-related risk factors: alcohol or drug use, obe-
sity, tobacco habit, exposure to a range of environmental toxins, etc. [3, 4] Consequently, 
studies assessing pregnancy rates or time to pregnancy following cessation of contraceptive 
use may be influenced by many underlying factors specific to the population under study.
Future pregnancy complications and pregnancy outcome is another important concerning 
issue of women who want to become pregnant; these events can happen in any pregnancy. 
Spontaneous abortion is one of the most common pregnancy complications; abortion rates 
are especially high in the weeks [5]. 14% of pregnancies end with fetal loss, with rates vary-
ing between 9% and 75% or more depending on the age, population and other factors [6, 7]. 
Ectopic pregnancy incidence rates vary between 1 and 2% of live births in developed coun-
tries, maybe reaching up to 4% in women subject to assisted reproductive treatments [8]. 
Preterm birth rates range from 5% of babies in European Countries to 18% in African coun-
tries [9]. Induced abortion rates also vary greatly depending in many psychosocial factors [7].
At the time of choosing a contraceptive method, women value aspects such as effectiveness, 
comfort, price, safety and early recovery of fertility after ceasing using this method. Past expe-
riences with contraception and future fertility intentions also can play a role in this decision. 
Quite often the reversibility of the method is an important concern for women; the lack of 
information plus the acquisition of misconceptions about methods can increase general mis-
trust in long-acting contraceptive methods and lead to reduced use of these. The midwife can 
exert an important role solving women doubts, considering their concerns and helping them 
choose the most suitable contraceptive method in each case.
Male condom was the mainstay of contraception for several decades, being also immediately 
reversible and effective at preventing sexually transmitted diseases (STDs). Combined Oral 
Contraceptive (COC) Pill, which contains estrogens and progesterone, was first approved for 
contraceptive use in the United States in 1960. Combined hormonal methods also include patches 
and vaginal rings. Unlike combined methods, progesterone-only contraceptive methods are not 
associated with cardiovascular risk or deep-vein-thrombosis risk. These methods are monopha-
sic and can be administered subcutaneously or orally (progesterone-only pills, POP). They lack 
adverse effects on lactation but cycles and menstrual bleeding become more irregular [10].
Long-acting reversible contraception methods are highly-effective reversible contraceptive 
methods that last for years and are easy to use. These include the intrauterine device (IUD) and 
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the birth control implant. The pregnancy rates in these methods are comparable to sterilization. 
IUD risks include uterus perforation, IUD loss, pelvic inflammatory disease, pregnancy dur-
ing IUD use, etc. [11] Depot medroxyprogesterone acetate intramuscular injection (DMPA) was 
approved by the FDA in 1992 and became the most common injectable method in use in the USA 
[12]. LARC has been described to be more cost-effective than COCs, even at 1 year of use [13].
Women’s preferences for anticonception have varied between different countries and gen-
erations [14, 15]. As a documented example for these variations, in the USA the Centre for 
Disease Control has published several periodic reports on contraception use. Apparently in 
the 2006–2010 report [16] a slight decrease in condom usage and an increase in intrauterine 
devices (IUD) was observed compared to 1995 data.
The 2011–2013 National Survey of Family Growth reported that oral contraceptives (OCs) 
were the most commonly used contraceptive method in the United States (16% of women 
aged 15–44), followed by female sterilization (15.5%), male condom (9.4%) and long-acting 
reversible contraceptives (7.2%). The use of sterilization declined and the use of OCs increased 
with greater educational level and the use of long-acting reversible contraceptives was higher 
among women aged 25–34 (11.1%) compared to other age groups [17].
This chapter focuses on a particular clinical situation: those women who are using a contra-
ceptive method and want to conceive a child. These future mothers are often worried about 
when they will be able to conceive and about the health of the future child. With the advent 
of the Internet and information technologies the access to information has become less of a 
problem compared to the information overload [18] and the abundance of lesser quality infor-
mation. Generally speaking openness of information is positive for patients, but many issues.
Some women might have heard reports of secondary effects of contraceptive methods and 
they might become concerned about this; on the Internet many women talk and discuss 
reproductive issues via women’s forums or family planning forums and this might exacer-
bate some natural fears of mothers. In these cases it is especially important to expose medical 
evidence-based facts clearly: many contraceptive methods have been available for decades 
and there is abundant evidence and clinical experience with them. More than 150 million 
women around the world use the IUD [15] and clinical studies with contraceptive methods 
have involved thousands of patients [1]. Case reports are seen as particularly weak evidence 
when compared to other studies, and personal experiences shared via the Internet should not 
be considered a reliable source of information. For example, a former user of IUD could have 
a miscarriage and she could link these two circumstances; attempts to rationalize this situa-
tion are normal part of the grief and emotional healing process in many women. However 
miscarriages are very common (some authors have calculated a rate of >20 miscarriages/1000 
women/week in the first 8 weeks [5]) and she might just be experiencing a fortuitous event.
Press and internet newspapers can act as an immediately available and quite reliable bridge 
between authoritative media sources and women. Reports on contraceptive methods some-
times include expert opinion and consensus statements [19]; information presented this way 
could be helpful for women. Media sources also usually include noteworthy journalists’ opin-
ion articles on reproductive issues [20]; in these the separation between facts and beliefs could 
be less clear. Experienced midwifes and doctors can also act as a reliable bridge for women 
with reproductive health doubts; they can provide objective evidence-based objective infor-
mation and statements that can be very helpful for women.
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Over the course of many decades contraceptive methods have deeply improved. Secondary 
effects of oral contraceptives have been detected and lower dose formulations have been devel-
oped. Many studies have assessed long-term effects of OCs on various aspects of women’s 
health [14, 21], including their future reproductive health. In some topics conflicting evidence 
is available as the results and conclusions of some studies differ from others. This is not the case 
for contraceptive reversibility (which has consistently been observed for decades in many stud-
ies and is remarked in NICE [13] and WHO [22] guidelines, as we will discuss later), but for 
some rare pregnancy events (twin pregnancy, preterm birth). Obtaining contradicting results is 
not uncommon in clinical research and does not necessarily imply there was a flaw conducting 
the study [23]. Publishing these studies is not a mistake, but inadequately interpreting them 
could be. Conflicting and inconclusive evidence should be treated with special caution; uncon-
firmed results or contradictory results are not ground for evidence-based recommendations.
In this chapter we will analyze the reversibility of physiological changes, the observed fertil-
ity changes and the future pregnancy complications of several contraceptive methods: OCs 
(including progestin only pill and emergency contraception), injectables, implants and IUDs.
2. Oral contraceptives
2.1. Cessation
The pathway in women using OCs to return to fertility is often straightforward. The informa-
tion leaflet of the particular regime often includes clear and specific instructions for women 
seeking discontinuation and pregnancy (which often only consist of ceasing its use). Women 
are often advised to wait for their menstrual period before seeking a new pregnancy because 
the day of the last menstrual period is useful in pregnancy date calculations. In our center, 
midwifes provide preconceptional counseling, which can include contraception recommen-
dations and assessment (this applies to contraception in general). Many health issues affect-
ing the health of the mother and the future baby can be addressed in these visits [24] and we 
can only recommend this practice.
2.2. Physiology
The mechanisms of action of oral contraceptives (OCs) are derived from the effect of the estro-
gen and the progestin in the formulation. Estrogens act by inhibiting follicular development 
and inhibiting hypothalamic–pituitary ovulation trigger. Progestins increase the thickness of 
the cervical mucus. The effects of Oral Combined Contraceptives (COCs) on endometrium 
vary depending on the doses, formulation and duration of use; with current commonly used 
lower doses contraceptives these effects include arrest of glandular proliferation, abortive 
secretion, stromal hyperplasia, decidualization and atrophy [25]. Intramuscular or locally 
administered progestins cause endometrial atrophy [26].
There is not much information on the reversibility of these changes. For example, cervical 
mucus can have lower scores for the first 2 months after discontinuing OCs and decreased 
menstrual flow was described to last for four months [27]. Some studies have linked reduced 
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endometrial thickness and long-term COC usage: Talukdar et al. studied the effect long-term 
use of combined oral contraceptives on endometrial thickness. They gathered 137 women 
between 30 and 45 years old subject to frozen embryo transfer cycles and determined the 
endometrial thickness on day 10. The group with endometrium thin than 7 mm (n = 30, a pro-
posed threshold for successful implantation) had longer COC usage compared to the rest of 
the women. Authors this could be mediated by the effects of OCs on stem cells in an inactive 
endometrium. In particular, some authors have said this effect after long-term use of OCs is 
“infrequent but persistent” [28]. These results should be taken cautiously and require further 
confirmation in larger groups of healthy women in prospective studies; as we will discuss 
later infertility has not been associated to OC.
The effects of COCs on gonadotropins have also been studied: Compared to women who 
never used COCs, women using them showed similar or slightly lower FSH levels, whereas 
women who used them showed slightly higher FSH levels that seemed to wane over time. 
(LH showed a similar pattern, but it was only significant in one of the two study groups). 
The authors attributed this to a possible rebound effect of gonadotropins after withdraw-
ing the hormonal COC and a suppression of endogenous estrogen and progesterone [29]. 
After withdrawal of COCs normal physiology is gradually restored: in a study with 24 
women it was observed that the first cycle is longer and with lower gonadotrophin levels 
compared to the third cycle; ovulation changes were observed in 17/24 women in the first 
cycle and in 21/24 women in the third cycle [30]. Recent use of OCs and their long-term 
use have been associated with longer follicular phases (longer time to ovulation) by some 
authors, but they acknowledged there are conflicting results on this issue in the literature 
and many women might choose to start using OCs to help regulate their cycles, which 
might already be longer [31].
Estrogens are known to stimulate prolactin production. Some reports associated post-pill 
amenorrhea and galactorrhea and serum prolactin is elevated in OC users; this is more pro-
nounced in women who use high-dose OCs but not significant association was found with 
long-term usage [32]. However prolactin levels do not seem to be altered in women who 
previously used COCs [33].
2.3. Return to fertility
Despite these described biochemical or histological findings, the reversibility of OCs has been 
clinically observed for decades and across many different ethnic groups (Table 1); many stud-
ies have reported 1 year pregnancy rates between 70 and 90% and 2 years pregnancy rates of 
80–90% [1, 34].
In the 1960s, the “postpill amenorrhea syndrome” was described as amenorrhea, anovulation 
and reduced reproductive fecundity for more than 1 year following discontinuation of OCs 
in some women who previously had regular menstruation. Some authors noted that many 
women with this syndrome exhibited oligomenorrhea before starting oral contraceptive 
usage [35]. It was thought that the exogenous administration of hormonal therapy with OCs 
delayed the return to normal function of the hypothalamic-pituitary-ovary axis [36]. Some 
authors advocated “watchful waiting” in women not seeking pregnancy, mentioning that 
regular menses tend to reappear after 12–18 months, and emphasized the importance of ruling 
Contraceptive Methods and the Subsequent Search for a Pregnancy
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Study design Method Participants Subjects Exposure 
(months)
1-year 
pregnancy rate
2-year 
pregnancy 
rate
Comments
Pardthaisong 
[34]
Retrospective 
and 
Prospective: 2 
arms
Depo provera 
(DMPA) vs. 
IUD
796 DMPA vs. 125 IUD Mean age:24.5 
vs. 27.7
Not reported 78.2 vs. 79% 92.1 vs. 
93.3%
Median delay to conception: 
DMPA: 5.5 months. IUD 4.5 
months
Harlap and 
Baras [109]
Retrospective 1403 OC
4477 other 
contraceptives
The proportion of pill users who conceived in the first 
month was 30% less than the others, but by the third 
month this difference had disappeared
Belhadj et al. 
[110]
Randomized, 
prospective
Mirena IUD 
20mcg/d vs. 
CuT380Ag
110 females >90% Median time to planned 
pregnancy was 3 months 
for the TCu 380 Ag group 
and 4 months for the 
Levonorgestrel 20 group
Skjeldestad 
et al. [111]
Prospective 
observational
Copper IUDs 101 IUDs users (Nova 
T, MLCu 250 vs. MLCu 
375) Norway
Mean age 28.3 56% <24m 85% 93%
Affandi et al. 
[112]
Prospective Implant 80 Implanon vs. 80 
Norplant Indonesian 
women
Mean age 
~28.0 y. Mean 
parity ~ 2.3
35.3 ± 13.1 vs. 
55,8 ± 17.7
48.8 vs. 37.5% 60.0 vs. 
73.8%
Wilson et al. 
[106]
Prospective IUD 1051 IUD. New 
Zealand
375 nulligravid 
676 gravid 
women
Not reported Not reported 91.5 vs. 
95.7%
Removal because of 
complications: No reduction 
in fertility or increase 
in ectopic gestation, 
miscarriage, or preterm 
delivery rates in 12 months
Gupta et al. 
[113]
Prospective IUD (8 types: 
6 Cu-bearing, 
progestasert 
IPCS 52 and 
Lippes Loop)
91 users India. Mean age 
~27.6
22.9 m 92.3% 96.7%
Silvin et al. 
[114]
Prospective, 
multicenter
Norplant vs. 
Norplant II
178 users (62 vs. 116) Mean age ~ 
27.45
Mean 31, 35 
months
83 vs. 84% 87 vs. 92%
Family Planning
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Study design Method Participants Subjects Exposure 
(months)
1-year 
pregnancy rate
2-year 
pregnancy 
rate
Comments
Randic et al. 
[115]
Prospective, 748 parous (planned 
pregnancy) 2713 
(complications)
Mean age: 27.1 
(first group)
82.9% 89.5%
Andersson 
et al. [116]
Prospective IUD 209 IUD users (71 
Nova-T vs. 138 IUD 
– LNG)
Mean 27 y Median 21 
months (range 
6–53)
71.2 vs. 79.1% 79.7 vs. 
86.6%
Tadesse [117] Prospective Copper T200 780 users. Ethiopia Mean age 29 
Nulligravid: 
3.2% multip. 
93.5% grand 
multip: 3.3 %
Mean 3.5 years 86.6% No data
Buckshee 
et al. [118]
Prospective Subdermal 
Implant 
(Norplant II)
627 India 18–35 years Mean 55.8 ± 
17.7 m
80.3% 88.3%
Bahamondes 
et al. [95]
Prospective Injectable 
(Cyclofem)
70 users Brazil, Chile, 
Colombia and Peru
Mean age 
~25.6
Mean number 
of injections: 
7.1 ± 4.6
82.9% Not 
reported
Return of fertility was not 
related to the woman’s 
age at the time of 
discontinuation, her weight, 
or the number of Cyclofem 
injections.
Zimmerman 
et al. [119]
Prospective 
observational
OC 348 users of 30 mcg EE 
/ 2 mg DNG (Valette)
Mean age: 
26.8 y
Median 4–6 
months
95% Not 
reported
Delbarge 
et al. [120]
Prospective IUD Gynefix 128 users Mean age 
30.5 y
104.6 ± 93.5 
weeks
88% 99% No statistical differences in 
pregnancy rates were found 
for age and duration of use 
of the IUD
Farrow et al. 
[42]
Retrospective OC 8497 users who 
conceived intentionally 
South-west England
Mean age 28 From 1 to more 
of 5 years: >5: 
56.8% of the 
participant 
3–4: 20.3%, 1–2: 
11%, <1: 7%, 
never: 4.9%
According to 
years of use: 
>5: 89.5%, 
3–4: 88%, 1–2: 
85.2%, <1: 
83.5%
Mean 
96.6%
The article includes many 
analysis categories, such 
as woman’s alcohol 
consumption or cigarettes 
smoked
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Study design Method Participants Subjects Exposure 
(months)
1-year 
pregnancy rate
2-year 
pregnancy 
rate
Comments
Hov et al. 
[121]
2 branches. A: 
Prospective
Copper IUD 205 users Norway (A: 
109 IUD removed due 
to wish to be pregnant 
vs. B: 96 IUD removed 
due to complication)
90% (group A). 93.6 vs. 
98%
No difference in cumulative 
probability to become 
pregnant by parity, duration 
of IUD use and age upon 
removal of IUD
Wiegratz 
et al. [44]
Prospective 
observational
OC: 30 microg 
ethinyl E2 
and 2 mg 
dienogest 
(Valette)
706 users Germany Mean age: 26.8 21.5m ± 16.8m 
(median 16m)
86.6% (more 
than 15.5% 
in the first 
3 cycles) 
Meantime 3.5 
cycles
not 
reported
Cronin et al. 
[46]
Prospective 
cohort
OC 
(drospirenone 
and other 
progestins)
2064 users Mean age 28.1 
years
2.8 ± 0.8 years 21.1 % after first 
circle. 79.4% 
1-year
88.3%
Stoddard 
et al. [122]
Prospective IUD 69 IUD (50 Cu, 19 
LNG) vs. 42 non 
IUD. St Louis, USA.
Mean age: 27.6 
vs. 29.5
81 vs. 70% 
(p=0.18)
Abdinasab 
et al. [123]
Retrospective 
cohort study
Cu IUD 
(T-380)
750 non-nulliparous 
Iranian women 375 
Cases: history of using 
Cu T-380A IUD > 5 
months. 375 Controls: 
history of other 
contraceptives: OCP, 
withdrawal method, 
male condom.
Mean age: 34.8 
vs. 33.9
57.46 ± 47.74 m Mean length from Cu 
T-380A IUD removal to 
pregnancy was 14.87 ± 5.18 
months
Table 1. Studies evaluating return to fertility.
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out other causes of amenorrhea [37]. Some women with amenorrhea after discontinuing OCs 
could have preexistent menstrual irregularities masked by OC. In the 1980s more reliable 
studies showed no association between oral contraceptive use and secondary amenorrhea 
and lack of specific findings in this syndrome [38]. Current practice holds that women who do 
not menstruate 3 months after discontinuing COC usage should be evaluated like any woman 
with amenorrhea [39].
Diana Mansour published in 2010 an interesting comprehensive review of the literature 
assessing pregnancy rates following discontinuation of several contraceptive methods; 17 
prospective studies were included. One year pregnancy rate following cessation of OCs (3 
studies) ranged from 79.4 to 95% and median time to pregnancy, estimated from available 
data, was 2.5–3 cycles) [1].
The Oxford-FPA study, published in 1978, was one of the first studies that investigated this 
issue. In this prospective cohort study 12 months after contraception cessation 70.1 of women 
who used OCs remained undelivered, which is significantly higher than 46.4% for the dia-
phragm group or 47.6% for the other methods group. After 36 months the differences became 
non-significant [40].
Doll et al [41] performed a study in nulliparous women from 17 family planning clinics in 
England and Scotland; they found that duration of oral contraceptive use was linearly associ-
ated with decreased fertility and that return to fertility is slower in users ceasing OC (32% 
delivery after 1 year) compared versus users ceasing IUD (39%) or users abandoning barrier 
methods (54%); 18 months after ceasing using contraceptives these values were 70% delivery 
for previous OCs group, 67% delivery for previous IUD group and 76% delivery for the bar-
rier method group. Authors observed significantly faster return to fertility for users of barrier 
methods (log rank test, p = 0.002) without statistical differences between OCs and IUDs. Other 
studies usually report around 1-year conception rates (>80%) [42]. Temporary (a few months) 
delays in fertility have been observed in other studies in women using OCs [43, 44] and reflect 
physiological changes: some women return to fertility faster than others. In this study dura-
tion of OC use had no significant effect on fertility and women who interrupted OCs and used 
barrier methods for 3 months had faster return to fertility than those who tried to conceive 
immediately after stopping using OCs [41]. After 42 months of ceasing OCs 11% of women 
had not delivered a baby.
A recent Danish prospective cohort study also observed a temporary reduced fertility in the 
3 months after OCs discontinuation compared to barrier methods, but pregnancy probabili-
ties became similar thereafter [45]. From the Kaplan–Meier curves time to pregnancy (TTP) 
percentiles were obtained, the 25th, 50th (median) and 75th percentiles were 2, 3 and 7 cycles 
for women who had discontinued barrier methods and 2, 4 and 9 cycles for women whose 
last method were OCs. A dose–response relationship between time using OCs and increased 
fecundability was observed, with confidence intervals becoming significant after 10 years of 
use. High-dose OCs was associated with shorter TTP. This study has some limitations, but the 
conclusion is very reasonable: there is no evidence that using OCs for years impairs fecund-
ability. Other studies have also showed that long-term OC use is not associated with reduced 
fertility [46], but not all studies agree on this matter [47].
Contraceptive Methods and the Subsequent Search for a Pregnancy
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The effect of other variables (weight, smoking …) on time to fertility after OC discontinuation 
has been evaluated in many studies, but small sample sizes limit the interpretation of these 
results [1].
Many studies do not evaluate COCs and POP separately or focus only on the former. POPs 
have not exhibited delays in the return of fertility [48]. With Norgestrel pills conception can 
occur within once cycle of stopping the medication [49]. In a randomized open-label study 
with 103 women after discontinuing a desogestrel-only pill ovulation appeared as early as 
7 days, with an average of 17.2 days; [50] (with traditional POP ovulation occurs in 30–40% of 
users, but this pill has a remarkable anovulatory effect shared with combined formulations).
Emergency oral contraception (mifepristone) does not harm future fertility [51] and woman 
should be informed that emergency oral contraceptives do not protect from future pregnan-
cies. In women who had successful abortive expulsion of the gestational sac the mean times to 
ovulation after mifepristone administration was 20.6 days (±5.1; range 8–36) [52].
2.4. Pregnancy complications and outcomes
Some studies have linked previous OCs usage with twin conception [53, 54, 55], whereas oth-
ers have not observed this association or limited its findings to OCs with high doses of estro-
gen [56]. Increased levels of FSH are observed in mothers of twin pregnancies; the “endocrine 
hypothesis” of dizygotic twin pregnancies holds that high FSH is responsible for multiple 
ovulation [57]; it has been suggested this mechanism might be the link between OC usage and 
dizygotic twin conceptions. However many of the studies reported increased monozygotic 
twins rates. More recent evidence is lacking on this matter.
The effect of OCs on fetal loss has been studied for many decades. The first studies did not 
find any link or described the effect of OCs as protective [53]. Some studies have shown con-
sumption of oral contraceptives for more than 9 years could protect against miscarriage [58]. 
On the other hand a Spanish retrospective [59] case–control study (N = 300) did actually iden-
tify taking oral contraceptives for more than 2 years before pregnancy as a risk factor of mis-
carriage (OR: 2.56, 95% CI: 1.16–5.67); the statistical methods included a step-wise regression, 
a controverted statistical procedure known for its risk of spurious associations. The authors 
hypothesized that the endometrial atrophy associated to taking (modern) low-dose oral con-
traceptives for extended periods of time could cause miscarriage or that acquired activated 
protein C resistance could be the link between oral contraceptives use and miscarriage.
A Danish prospective cohort study published in 2016 did not confirm these findings; 4500 
women participated in this study. The hazard ratios were all non-significant and smaller than 
1; the study did not find association between spontaneous abortion and discontinuing oral 
anticonceptives closer to conception (categories: discontinuing 0–1 months before concep-
tion, 2–6 months or 7–12 vs. discontinuing more than a year (reference) before conception); 
or between spontaneous abortion and longer use of oral contraceptives (comparing less than 
4 years COC usage (reference) vs. 4–7 years, 8–11 years and equal or more than 12 years) [60].
The Jerusalem Perinatal Study is a cohort study that recorded several variables on 92,408 
live neonates and stillbirths from the 1964–1976 period and on their families; these data were 
linked to several registries and many epidemiological studies were carried out [14]. For 
instance, in this study former COC usage conferred no risk of obstetric complications [61].
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The relationship between OCs and birth weight has been controversial in the literature. A 
study with 260 Boston women found previous OC use increased birthweight and placental 
weight compared to non-users [62] with more pronounced effects in women with longer use 
and with stronger hormonal contraceptives. The authors suggested this effect might be medi-
ated by the higher levels of estradiol and progesterone observed in former users.
A 2015 Danish prospective cohort study evaluated the effect of oral contraceptives usage 
before pregnancy on birth weight [63]. The authors used data from online questionnaires and 
from the Danish Medical Birth Registry; 5921 women were followed for 12 months and 4046 
live births took place. After adjustment for several confounding variables women who had 
discontinued OCs less than a month before conception exhibited higher mean birth weight 
(97 g, 95% CI: 26–80 g) compared to those who discontinued more than 12 months before 
conception; and lower mean birth weight was observed in women with previous >12 years of 
OCs use vs. <4 years (−85 g, 95% CI: −158, −11).
Previous use of OCs has not been consistently associated with birth defects on the offspring. 
Some studies old studies found this link [55] but other studies did not. In a cohort (n = 732) from 
the Jerusalem Perinatal Study children were tested up to 3 years age. Although some dim trend 
in IQ values was suggested, those whose mothers were OCs users did not exhibit statistically 
significant differences in weight, height, development quotient or intellectual quotient [64].
It might occur that a woman accidentally and unknowingly takes oral contraceptives for 
some period after conception, a situation sometimes called breakthrough pregnancy, thereby 
exposing the fetus to doses of estrogens or progestins. This situation is especially worrying 
and distressing for affected women. In the past a frequent case of fetal exposure to potent 
oestrogens was that of women prescribed diethylstilbestrol (DES) in pregnancy to prevent 
abortions; after a study [65] linked this to vaginal clear-cell carcinoma in 1971 the FDA banned 
this drug in pregnant women. The daughters of women treated with DES in pregnancy have 
shown increased risk of cervical and vaginal precancerous states, a possible slight increase 
in breast cancer in women older than 40 years old, reproductive tract structural anomalies, 
infertility and pregnancy complications. The sons of treated women may be at increased risk 
for epididymal cysts and maybe other genital abnormalities. The NIH and the CDC provide 
information for healthcare providers and patients on this public healthcare issue [66, 67].
Several studies have evaluated how the use of oral contraceptives with way less estrogenic 
potency compared to DES after conception could influence male hypospadias and urinary 
tract anomalies, but the results have been inconclusive and contradictory: In some studies 
the association was clear [68], but others did not observe this association [69]. A recent 2009 
large Danish case–control study evaluated the relationship between use oral contraceptives 
after conception and male hypospadias. This study used prescription data rather than self-
reported maternal exposure data in order to prevent the recall bias, a relevant cause of spuri-
ous associations in retrospective case–control studies. The adjusted prevalence ratios were 
close to one and none of them was significant: for example 0.85 (95% CI: 0.65–1.28) for expo-
sure to COC in early pregnancy and hypospadias detected within 6 months postpartum [70].
Women with breakthrough pregnancies or conception close to OCs cessation should also be 
assured large studies have not identified increased prevalence of birth defects. A meta-analysis 
published in 1990 found no association for OC exposure early in pregnancy and heart defects or 
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limb reduction defects [71]. Charlton et al. collected data on OCs use and major birth defects on 
880,694 live births from Danish registries; the prevalence of major birth defects (per 1000 births) 
was 25.1 for never users of OCs, 25.0 for OCs used more than 3 months before conception, 24.9 
for OCs used less than 3 months before conception and 24.8 for OCs used after conception; the 
confidence intervals were not significant, and association was not found either for prevalences 
by defect subgroup [72]. Older studies (with older contraceptive formulations) arrived to more 
or less similar results: No significant association was observed between congenital malforma-
tions and conceiving within 1 month of stopping OC, and in breakthrough pregnancies the 
ratio of observed to expected major malformations was only significant in mothers one pack or 
more of cigarettes daily [73]. A recent study in 2010 (with 4000 healthy controls and 9986 infants 
with birth defects) did not find association for 32 anomalies when OCs usage took place before 
conception and only found association for gastroschisis (OR 1.82, 95% CI 1.25–1.67) and hypo-
plastic left heart syndrome (OR 2.33, 1.28–4.25) when OCs usage took place afterwards [74].
POPs have some particular characteristics regarding pregnancy outcomes. If the contracep-
tion fails a higher incidence of ectopic pregnancy versus other contraceptive methods has 
been described, but the incidences were similar to those in women not using contraceptives 
[12]. A proposed explanation is a reduction in the activity of fallopian tube cilia and tubal 
motility alteration [75]. Fetal male hypospadias was more likely to occur among women who 
took progestogens to prevent pregnancy complications or to help with becoming pregnant 
between a month before conception and 3 months after this point (reaching adjusted OR > 3, 
and stratified OR > 2). However the association was non-significant for those women who 
took progestogen as a contraceptive [76].
A Norwegian study published in 2015 evaluated the risk of preterm birth and found this risk var-
ied depending on the moment of exposure and the progestin used. COCs with Norethisterone 
were particularly associated with preterm birth in some exposure periods (with adjusted OR 
reaching 3.33 (95% CI: 1.69–6.57 for the period 0–12 weeks after conception, a period that 
seemed particularly critical in some subgroups); for COCs with Drospirenone or Levonogestrel 
or POPs the association seemed weaker or absent. Authors noted the association for preterm 
birth seemed consistent across all exposure periods, but they also acknowledged other con-
founding factors could explain this association. Authors pondered a weakly estrogenic environ-
ment could be deleterious for fetal growth. The study also evaluated birth weight using z-scores 
(a more precise and current definition) and found no association with OCs [77]. A cohort study 
in China agrees with this association (OR for OCs usage in multiple logistic regression: 8.162, 
95% CI: 1.622–41.072) [78]. Other studies found that exposure to OCs in the 6 months before con-
ception was associated with higher birth weight compared to longer duration exposures [63].
There is no evidence that Emergency Contraception is associated with worse outcomes in future 
pregnancies. The pregnancy outcomes of women undergoing mifepristone-induced abortion 
were studied in nearly 15,000 pregnant women in China. There were no statistically significant 
differences in preterm delivery, frequency of low birth weight or mean infant birth weight 
when comparing these women with those with surgically induced abortion. When comparing 
mifepristone-induced abortion and women without previous abortion the former had higher 
mean birth weight and no significant differences in pregnancy length [79]. Other studies have 
found the outcome of medically terminated pregnancies is similar to those of mothers without 
them and better than those of mothers with surgically terminated pregnancies [80].
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Some authors have noted in the last years we have observed increasing rates of OCs use as 
well as increasing rates of Autism Spectrum Disorder diagnoses and have raised hypotheses 
regarding specific consequences in the offspring; this remains to be elucidated in future clini-
cal studies [81].
2.5. Conclusion
It seems clear that fertility returns promptly with OCs and that any delay to return to normal 
physiology does not remarkably influence 1 year or longer fertility rates. There’s no consistent 
evidence to conclude OCs are associated with future miscarriage, preterm birth, low birth 
weight or hypospadias.
3. Implants and rings
Removing the implant is often an easy and uncomplicated procedure. In a clinical trial per-
formed by Bahamondes et al., women perceived the pain of the as none (444, 86%), mild (65, 
13%), moderate (8, 2%) or severe (0) for the ENG (etonorgestrel) implant; and none (252, 81%), 
mild (49, 16%), moderate (6, 2%) or severe (1%) for the LNG (levonorgestrel) implant [82]. The 
ease of removal was reported as easy (492, 94%), slightly difficult (22, 4%) or difficult (8, 2%) 
for the ENG implant and easy (254, 81%), slightly difficult (47, 15%) or difficult (12, 4%). In 
this study, two (0.4%) ENG removals were complicated (the implant broke) and seven (2.2%) 
LNG removals were complicated (in seven cases the implant broke).
The ACOG has published some recommendations regarding the clinical challenges posed by 
LARC, including the implants [83]. Ultrasonography can be helpful if the implant is impal-
pable when removal is attempted [84]; in rare cases magnetic resonance might be required to 
locate it.
There is no evidence fertility is delayed after removal of contraceptive implants [13]. In a 
study Etonogestrel became not detectable within 1 week of removal of Implanon® implant 
[85]. Pregnancies have been observed to occur as early as 7–14 days after removal [86]. Within 
1 month of Implanon removal ovulation has been observed to return in 40% (16/40) women; 
and 12 months conception rate was 96% (23/24) in women who had the implant removed and 
did not implement other contraceptive methods [87].
NuvaRing® is the only ring available to the United States; it releases 15 μg ethinyl estradiol 
+120 μg etonogestrel per day (which are rapidly absorbed through the vaginal epithelium 
[88]) and lasts 3 weeks. Ovulation returns after removal of the vaginal ring (in a mean time of 
19 days [89]). In the majority of women who discontinue NovaRing ovulation and spontane-
ous menstrual cycles return within a month [90].
Many other contraceptive preparations are being developed, and prompt return of fertility is 
usually the rule. After discontinuation of a transdermal patch ovulation has been described to 
return in the first cycle in 86% of women [91].
The considerations on pregnancy outcomes for OCs can be extrapolated to those methods in 
which estrogens and progestogens are administered non-orally.
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4. Injectable contraceptives
Injection-based methods differ from other methods in the return to fertility since they are irre-
versible in the short-term, but fertility rates eventually reach those of them [13]. In this group 
methods one year pregnancy rates range between 72.5–82.9% with median time to pregnancy 
being 4.5–5 months [1].
Depot medroxyprogesterone acetate (DMPA) is the most commonly used injectable, being 
administered as intramuscular injections every 12 weeks. Product leaflet mentions some preg-
nancies have occurred 14 weeks after a preceding injection but longer delays are common: 
the observed mean time to ovulation is 5.3 months and the median time to conception is 
10 months after the last injection. About 83% women should conceive within 15 months of the 
last injection [92].
A large study in over 1000 Thai women remarked that return to fertility and proportions of 
live births in the offspring of women who used MDPA are similar to those of women using 
other contraceptive methods (OCs or IUDs): in this study the median delay to conception 
for MDPA was 5.5 months plus the estimated effect duration of the last injection; this can be 
compared to 3 months for OCs and 4.5 months for IUD [93].
Intramuscular injections of norethisterone enanthate acts as a contraceptive for 8 weeks; in 
11 of 20 women discontinuing this method follicular activity was observed within 90 days 
of the last injection [94]. The observed median delay to conception is 6 months after the last 
injection; 14 of 40 women became pregnant within 12 weeks and 31 of 40 after 1 year. Authors 
remarked the real figures could be higher. The delays in fertility were not correlated with the 
duration of use.
Intramuscular injections of estradiol cypionate and medroxyprogesterone acetate (Cyclofem®) 
are administered every month. 1.4% women became pregnant at the end of the first month 
(since the first missed injection), 52.9% after 6 months and 82.9% after 9 months. Pregnancy 
outcomes were favorable: 51 (94.4%) pregnancies ended in a live birth [95].
5. IUD
5.1. Use cessation
The procedure to extract the IUD is often uncomplicated. A speculum and a Foerster clamp 
are needed: The speculum is inserted into the vagina until the cervix and the IUD threads 
appear through the external cervical os. The threads are fastened with the clamp and pulled 
until the total extraction of the IUD. The best time for extraction is during menstruation since 
the cervical os is slightly more dilated than under normal conditions. Non-visualized IUD 
strings is a potential challenge, the most common cause being string retraction into the uterus. 
ACOG recommends sweeping the cervical canal with a cytobrush, a maneuver that often 
reveals them; if this is not effective, the algorithm includes ruling out pregnancy, confirming 
abdominal location of the IUD and evaluating the need for a laparoscopic removal [83]. Some 
women might describe slight temporary mood swings after LNG IUD removal.
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5.2. Physiology
IUDs elicit foreign body reactions, which turns the intrauterine milieu lethal for embryos, 
without significant extrauterine effects. In addition to this, different types of IUDs can alter 
previous processes through varying degrees: Mucus thickening, glandular atrophy and stro-
mal decidualization in LNG IUDs, spermatozoa decay and toxicity by Copper ions in the 
uterine cavity, transmission of noxa from the uterine lumen to fallopian tube, etc. [96, 97]. The 
histological changes were found to be reversible within some months. Unlike OCs, IUDs have 
not been observed to be associated with follicular phase length [31].
5.3. Return to fertility
Fertility is not impaired after IUD removal13. In Diana Mansour’s bibliographic review 1 year 
pregnancy rates for Copper IUDs were 71.2–91.1% for Copper IUDs and 79.1–96.4% for LNG 
IUDs (median time to pregnancy were 2–3.7 cycles and 4 cycles respectively)1. Currently 
there is no evidence of a delay in return to fertility after using an IUD [13]; in some stud-
ies >50% of women conceived within 3 months after discontinuing it [98]. Table 1 contains 
selected studies pertaining return to fertility after contraception.
The history of IUD devices includes some particular case of long-lasting health and reproduc-
tive consequences after IUD usage. Despite some previous attempts and projects some decades 
earlier, it was not until the 1960s that commercial IUDs made their way into the market with the 
approval of the Lippes Loop and the Safe-t-coil by the FDA in 1966. The Dalkon shield, intro-
duced in 1971, attempted to increase the surface of the endometrium in contact with the IUD and 
to increase retention rate; it included a multifilament tail string encased in Nylon [99]. Several 
reports associated this IUD with increased infection rates, septic abortions and deaths; apparently 
the multifilament string could allow vaginal bacteria to access the uterus. Since this IUD was used 
in many world countries the numbers of women suffering adverse consequences is difficult to 
estimate. Device sales stopped in 1974 and the company started to recommend device removal if 
a pregnancy took place, which is now standard practice; women experiencing the adverse events, 
which includes fertility impairment as sequel, filled many lawsuits and in 1980 the company rec-
ommended removal of the Dalkon shield in women who were still wearing them. Distrust and 
doubt regarding IUDs lasted for several years after this, especially in the USA [100].
The relationship between IUD usage and pelvic inflammatory disease (PID), a well-known cause 
of infertility, has been studied extensively for decades [101] and many studies had pitfalls [102]: 
Sexual habits as a confounding factor, diagnosis bias… The described incidence of pelvic inflam-
matory disease on IUD users is very low (1.6/1000 person-years) and particularly confined to the 
first weeks after insertion. Preventive strategies include adequate selection of IUD candidates, 
prophylactic antibiotic during insertion, careful monitoring and treatment of infections, etc.
Long-term usage is not associated with posterior infertility; several studies have shown preg-
nancy rates are not delayed in women who used copper IUDs for several years [106]. Zhu 
et al. performed a study with 1770 Chinese women who had their IUDs removed after a 
catastrophic earthquake in the Sichuan region and were followed up for two years [103]. 71% 
women conceived within 1 year after removal and 80% conceived within 2 years. In the mul-
tivariate logistic regression analysis age was negatively associated with fertility (OR 0.7548, 
95% CI: 0.7148–0.7933), while duration of IUD use (OR 1.0596, CI: 1.0244–1.0960) and previous 
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gravidity were positively associated. The authors described a clear reduction in fertility and 
increased miscarriage rates with age; 1 year pregnancy rate among women older than 40 years 
was 49.67%. They reported duration of IUD use was associated with decreased fertility but 
did not stratify the analysis of this variable and age could be a confounding factor. Women 
with longer IUD usage are also older women, and fertility and miscarriage rates are known 
to depend on age.
In the study by Doll et al [41] long-term IUD usage was associated with reduced fertility 
(log rank test for linear trend, P = 0.0035); authors hypothesized that this might be related to 
pelvic inflammatory disease This article received media coverage in the UK [104, 105], but 
remarking that most IUDs in this study were not available for women anymore and that cur-
rent standard practice included better diagnosis of infections. The posterior NICE Guidelines 
evidence review highlights that IUD female users were older and had higher rates of miscar-
riage, termination and ectopic pregnancy [13] and concludes that there is no evidence on 
delay in the return of fertility after discontinuing IUD usage. This also applies to nulliparous 
women, whose uterine cavity is usually smaller [15].
5.4. Pregnancy outcomes
One common concern of IUD users is the outcome of their future pregnancies. The different 
pregnancy outcomes observed in many studies with Copper IUD range from 84 to 88% for 
live births, 88–82% for term deliveries, 6–12% for spontaneous abortions, 1–4% for induced 
abortions and 0–2% for ectopic pregnancies (the studies classifications were not uniform) [1]. 
For LNG IUD the pregnancy outcomes are similar. Pregnancy outcomes of several studies are 
reported in Table 2.
Many studies have assessed the effects of IUD complications on fertility. In a 1989 study with 
copper IUDs by Wilson et al. with Neo-Zealand woman 16% (164) of IUD removals took place 
due to complications. 92.4% of these women had conceived after 36 months (compared with 
94.2% for the rest of IUD removals). Regarding pregnancy complications slight significant 
differences were observed only between some subgroups, which could be related to multiple 
comparisons in this study; for example in women who used IUD for less than 24 months, nul-
ligravid women had smaller conception rates than gravid women (86.7 vs. 93.6%, p < 0.005) 
[106]. Authors noted the observed outcomes in IUD users were similar or better compared to 
population ones. Other studies have also noted IUD removal was not associated to ectopic 
pregnancy risks [115].
In the unlikely event that a woman using IUD becomes pregnant it is advised that the device 
is removed before 12 completed weeks’ gestation, regardless of whether she wants or not to 
continue with the pregnancy [13]. These situations are associated with significant miscarriage 
and septic abortion risks.
Regarding PID, a dose–response has been established between the severity and number of 
episodes and ectopic pregnancy risk; for example in women aged 25–44 with 2 or more severe 
episodes the probability has been statistically modeled to be 84% [107]. These women have 
many options: careful follow-up, laparoscopy, in vitro fertilization, etc.
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Method Participants Term 
pregnancy 
(%)
Miscarriage 
(%)
Ectopic 
(%)
Preterm 
birth 
(%)
Induced 
abortion
Comment
Belhadji 
et al. [110]
TCu380Ag 17 pregnant 
women
88% 12%
Wilson et al. 
[106]
Copper IUDs 1051 IUD.
New 
Zealand
83.2% 11.6% 0.5% 2.0% 2.7% Similar rates 
to women 
from New 
Zealand, but 
higher rates 
of induced 
abortion. 
Authors 
attributed this 
to women’s 
attitudes and 
choices after 
the recall of 
another IUD.
Skjeldestad 
and Bratt 
[111]
Copper IUDs 95 pregnant 
women
88.4% 8.4% 2.1% 1.1%
Andersson 
et al. [116]
IUD 50 users 84% 6% 2% 4% 2% outcome 
unknown and 
2% still birth
Sivin et al. 
[114]
IUD
TCu380Ag
66 pregnant 
women
82% 15% 0% 3%
Tadesse, 
[124]
IUD Copper 
T-200
671 pregnant 
women
87.8% 8.5% 3.7%
Randić et al. 
[115]
IUD. 3461 
Croatian 
women
Ectopic pregnancy: Control: 3.9%, planned pregnancy 
(parous women) 2.7%: accidental pregnancy 0%; 
expulsion/displacement 1.2%; bleeding/pain + PID 6%. 
(Non-significant differences)
Lower rates 
than general 
population
Andersson 
et al. [116]
LNG-20 IUS 104 pregnant 
women
85.6% 5.8% 1% 2.9%
Sivin et al. 
[114]
LNG-20 IUS 68 pregnant 
women
89% 2%
Belhadji 
et al. [110]
LNG-20 IUS 22 pregnant 
women
86% 14% 17 women 
still pregnant 
at time of 
analysis
Buckshee 
et al. [118]
Norplant II 136 pregnant 
women
89.7% 4.4% 5.9%
Sivin et al. 
[114]
Norplant II 86 pregnant 
women
88% (term 
delivery)
8% 1% 1% 2%
Sivin et al. 
[114]
Norplant 33 pregnant 
women
93% (term 
delivery)
4% 0% 4%
Diaz et al. 
[125]
Norplant 75 pregnant 
women
79% (term 
delivery)
9% 5%
Contraceptive Methods and the Subsequent Search for a Pregnancy
http://dx.doi.org/10.5772/intechopen.72525
229
6. Other methods
Return to fertility with barrier methods is prompt and expectable, given the lack of effects on 
female physiology compared to other methods. The figures have been reported previously 
as reference group. One year delivery rate after discontinuation was found to be 54% in an 
English study, which was higher than COCs or IUDs [41].
Natural family planning does not involve persistent physiological changes on women; 1 year 
pregnancy rates and spontaneous abortion risks can be considered as similar to general popu-
lation ones. For example, a study observed abortion rates of 10.1% [108].
7. Clinical cases pertaining return to fertility
Case 1: barrier method of contraception.
An 18-year-old woman comes to a consultation for contraceptive advice. She has just started a 
relationship.
Personal history: without interest.
Family history: DM type II father. Mother HTA.
Menarche at 14 years.
Not pregnancies.
Planning: has not started relationships.
Method Participants Term 
pregnancy 
(%)
Miscarriage 
(%)
Ectopic 
(%)
Preterm 
birth 
(%)
Induced 
abortion
Comment
Bahamondes 
et al. [95]
Cyclofem-
monthly
58 pregnant 
women
98.4% 3.4%
Hahn et al. 
[60]
OC 4862 Danish 85.7% 14.3% (SAB) No evidence 
that pregravid 
OC use is 
associated 
with 
spontaneous 
abortions
Chen et al. 
[79]
Medical 
abortion 
(mifepristone) 
vs. surgical 
abortion vs. 
no abortion
13928, 
Chinese
2.9 vs. 
3.0 vs. 
3.7
(P<0.05)
Authors 
concluded 
no long-term 
consequences
Table 2. Pregnancy outcomes after using contraceptives.
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The most appropriate method? In this case the most appropriate method would be barrier contracep-
tives, since she does not yet have a stable relationship. If the patient requested it combined oral con-
traception could be considered, but in that case we will recommend to keep using barrier methods to 
prevent STDs (double contraception).
Case 2: Combined contraceptives (oral contraception).
Female, 26 years old. Stable couple for 2 years. She wants advice on contraception. She remarks she 
wants to have children at some later point in her life.
Personal and family history: no interest.
Menarche at age 13.
Nulliparous. Last cytology less than 1 year ago.
Menstruation: 6/30, quite irregular. Dysmenorrhea.
Previous recommendation: Barrier method (condom).
The most appropriate method? In this case we can recommend her oral combined contraceptives, since 
she has no remarkable diseases, has a stable partner and this will help in her dysmenorrhea and men-
strual pattern. We can assure her the reversibility of oral contraceptives has been observed for decades 
and that after interrupting them women’s fertility will be similar to the rest of women. She opts for 
oral contraception.
Case 3: Combined hormonal contraceptives (vaginal ring).
30 years old Woman with stable couple for 8 years. Uses oral combined contraceptives. She wants to 
stop taking a pill every day. She wants to have children at some point in the future and is afraid of 
pregnancy complications.
Personal and family history: no interest.
Not pregnancies. Last cytology 2 years ago, results: normal.
Menarche: 15 years.
Menstruation: 4/28, from taking contraceptives.
Planning: Combined oral contraceptives.
The most appropriate method? After explaining her the alternatives, she decides that she prefers the 
vaginal ring. We recommend how to start using this method after taking oral contraception. The ring 
should be administered as later the next day after the termination with the current pill. If the pill pack 
also has inactive tablets, she should start using the ring the day after the last inactive tablet.
Case 4: Subdermal Implant.
33 years old woman, she gave birth to a healthy son 2 years ago. She carries a subdermal implant and 
wants to become pregnant again.
Personal history: without interest.
Family history: Mother with breast cancer.
Pregnant: 3 years ago.
Menarche: at 15 years.
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Menstruation: 4/28.
Plan: Remove the implant, preconceptional counseling.
The implant is palpable and removed successfully. We advise her to wait for her period before attempt-
ing to conceive.
Case 5: IUD.
Female 34 years old. She does not want more children at the moment, but she does not want irreversible 
contraception since she does not know if she will want children in the future. She does not want to take 
oral contraception.
Personal and family history without interest.
Menarche to the 14 years.
Two vaginal births, 2 and 4 years ago.
Menstruation: 4/27, are not very abundant.
Planning: use a condom.
The most appropriate method? In this case we could offer the administration of an IUD, since it is 
reversible, but can last up to 5 years. We explain her that there is no conclusive evidence that long-term 
use of IUD leads to impaired fertility. Many other factors influence fertility, like aging or smoking.
Case 6: Irreversible.
A 42-year-old woman who visits her doctor after a 7-day menstrual delay. Demand planning advice.
Personal history: Hypothyroidism under treatment, varicose syndrome, smoking 15 cig / day. Intolerant 
to metallic chromium.
Menarche at age 12.
Two pregnancies and vaginal births, babies of 3900gr and 4100gr at 31 and 38 years.
Menstruation: 7/26, abundant since always.
Planning: coitus interruptus, because her husband does not “tolerate” the condom. Gynecological 
review less than 1 year ago with ultrasound and cytology, without alterations.
Conduct to follow: pregnancy test is performed, being negative. Menstruation at 3 days.
Which contraceptive method is the most appropriate? Given her age, having two children, the personal 
history, for this couple the best method of contraception would be vasectomy or tubal ligation.
8. Conclusions
None of the contraceptive methods described (OCCs, POP, emergency contraception, 
implants, rings, Cu IUD or LNG IUD) is associated with impaired fertility. A temporary 
delay in fertility can occur with COCs, but this does not alter 1 year conception rates signifi-
cantly. Injectable contraceptives are associated with delays in fertility buy not with fertility 
impairments.
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Previous OCs usage is not associated with birth defects and their effect on birth weight or 
preterm birth seems small and controversial (some associations have been detected in recent 
large and powerful studies, but a causal link remains to be confirmed).
In adequate large studies previous IUDs (Cu or LNG) usage has not been consistently associ-
ated with adverse pregnancy outcomes. There is not enough evidence to support the hypoth-
esis that long-term IUD harms future fertility.
Preconceptional counseling is advisable for all women who want to abandon contraception 
to get pregnant.
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